{"transactions":[{"id":757277,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-02T01:16:36.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":50000,"derivative":{"exercise_price":7.27,"expiration_date":"2036-05-27","underlying":"Series A Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-26-069124","document":"tm2616578-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000110465926069124/tm2616578-4_4seq1.xml","form_type":"4"}},{"id":890933,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-20T21:39:20.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":88000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":88000,"derivative":{"exercise_price":5.38,"expiration_date":"2036-02-18","underlying":"Series A Common Stock","underlying_shares":88000},"source":{"system":"sec-edgar","filing":"0001104659-26-018191","document":"tm266959-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000110465926018191/tm266959-1_4seq1.xml","form_type":"4"}},{"id":890932,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series A Common Stock","published_at":"2026-02-20T21:39:20.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":59688,"source":{"system":"sec-edgar","filing":"0001104659-26-018191","document":"tm266959-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000110465926018191/tm266959-1_4seq1.xml","form_type":"4"}},{"id":907755,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series A Common Stock","published_at":"2026-02-12T21:07:20.000Z","date":"2026-02-10","kind":"sale","planned":false,"acquired":false,"shares":1312,"price":5.3603,"value":7032.7136,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":15688,"source":{"system":"sec-edgar","filing":"0001104659-26-014277","document":"tm266207-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000110465926014277/tm266207-3_4seq1.xml","form_type":"4"}},{"id":1278904,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-07T21:41:47.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":69000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":69000,"derivative":{"exercise_price":4.71,"expiration_date":"2035-02-05","underlying":"Series A Common Stock","underlying_shares":69000},"source":{"system":"sec-edgar","filing":"0001104659-25-010584","document":"tm255919-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000110465925010584/tm255919-1_4seq1.xml","form_type":"4"}},{"id":1278903,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series A Common Stock","published_at":"2025-02-07T21:41:47.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":17000,"source":{"system":"sec-edgar","filing":"0001104659-25-010584","document":"tm255919-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000110465925010584/tm255919-1_4seq1.xml","form_type":"4"}},{"id":1523501,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-08T20:06:44.000Z","date":"2024-05-06","kind":"grant","planned":false,"acquired":true,"shares":587181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option shall vest and become exercisable on May 6, 2025, with the remainder vesting over thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":587181,"derivative":{"exercise_price":4.28,"expiration_date":"2034-05-05","underlying":"Series A Common Stock","underlying_shares":587181},"source":{"system":"sec-edgar","filing":"0001104659-24-058661","document":"tm2413886-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000110465924058661/tm2413886-2_4seq1.xml","form_type":"4"}},{"id":1912441,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2023-04-27T22:00:08.000Z","date":"2023-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":8.93,"underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-23-013902","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000149315223013902/ownership.xml","form_type":"4"}},{"id":1912440,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2023-04-27T22:00:08.000Z","date":"2023-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.39,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-23-013902","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000149315223013902/ownership.xml","form_type":"4"}},{"id":1912439,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2023-04-27T22:00:08.000Z","date":"2023-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":375000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":6.95,"underlying":"Common Stock","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001493152-23-013902","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000149315223013902/ownership.xml","form_type":"4"}},{"id":2056627,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-12T02:10:05.000Z","date":"2023-01-10","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest and become exercisable as to 25% on the one-year anniversary of the grant date (January 10, 2024) and the remaining 75% will vest and become exercisable monthly over 36 months such that the\noptions are fully vested and exercisable on the four-year anniversary of the grant date (January 10, 2027)."}],"balance_after":200000,"derivative":{"exercise_price":8.93,"expiration_date":"2033-01-10","underlying":"Common Stock, par value $0.0001","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-23-001207","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000149315223001207/ownership.xml","form_type":"4"}},{"id":2430901,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-20T22:17:43.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest and become exercisable as to 25% on the one-year anniversary of the grant date (January 18, 2023) and the remaining 75% will vest and become exercisable monthly over 36 months such that the options are fully vested and exercisable on the four-year anniversary of the grant date (January 18, 2026)."}],"balance_after":50000,"derivative":{"exercise_price":4.39,"expiration_date":"2032-01-18","underlying":"Common Stock, par value $0.0001","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-001745","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000149315222001745/ownership.xml","form_type":"4"}},{"id":2490880,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-12-02T02:16:30.000Z","date":"2021-12-01","kind":"grant","acquired":true,"shares":187500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were granted pursuant to the Issuer's 2020 Inducement Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 1, 2021 the Reporting Person was granted a stock option for 187,500 shares of Common Stock which vests in four equal annual installments commencing on December 1, 2021. Reporting Person was also granted 187,500 stock options under the Issuer's 2020 Inducement Plan with performance-based vesting triggers that will be reported, if and when vested, consistent with the applicable reporting requirements."}],"balance_after":187500,"derivative":{"exercise_price":6.95,"expiration_date":"2031-12-01","underlying":"Common Stock, par value $0.0001","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0001493152-21-030243","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000149315221030243/ownership.xml","form_type":"4"}}]}